United Therapeutics Corporation Revenue 2008–2025
United Therapeutics Corporation annual/quarterly revenue history and growth rate from 2008 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- United Therapeutics Corporation revenue for the quarter ending March 31, 2026 was 781.5 M, a 1.62% decrease year-over-year.
- United Therapeutics Corporation revenue for the twelve months ending March 31, 2026 was 3.2 B, a 15.38% increase year-over-year.
- United Therapeutics Corporation annual revenue for 2025 was 3.2 B, a 10.61% increase from 2024.
- United Therapeutics Corporation annual revenue for 2024 was 2.9 B, a 23.63% increase from 2023.
- United Therapeutics Corporation annual revenue for 2023 was 2.3 B, a 20.20% increase from 2022.
- United Therapeutics Corporation annual revenue for 2022 was 1.9 B.
United Therapeutics Corporation (UTHR) — Frequently Asked Questions
United Therapeutics Corporation (UTHR) is a publicly traded US company. It has a market capitalization of $26.06B. In fiscal 2025 it reported revenue of $3.18B and net income of $1.33B. Explore UTHR's stock price, financial statements, earnings history, margins and key ratios below.
What is United Therapeutics Corporation's market cap?
United Therapeutics Corporation (UTHR) has a market capitalization of $26.06B.
What is the UTHR stock price?
UTHR trades at $544.10 (-1.63% on the day).
How much revenue does United Therapeutics Corporation make?
United Therapeutics Corporation reported revenue of $3.18B in fiscal 2025.
Is UTHR profitable?
In fiscal 2025, United Therapeutics Corporation reported net income of $1.33B.